Loading organizations...
Medical device company developing Serration Technology for peripheral artery disease treatment, focused on angioplasty.
Founded in 2014 by medical technology entrepreneurs Carol Burns and Robert Giasolli, Cagent Vascular is a Wayne, Pennsylvania based medical device company developing advanced angioplasty technology for treating peripheral artery disease. Led by Chief Executive Officer Brian Walsh, the organization commercializes its proprietary Serranator device, a platform providing controlled lumen gain with minimal dissection that has seen adoption in over 20,000 clinical procedures. Operating with 34 employees, the enterprise generates approximately $8 million in annual revenue while expanding its product portfolio across the United States healthcare market. To accelerate commercial adoption, the company secured $45 million in equity financing led by US Venture Partners, alongside strategic investments from Sectoral Asset Management and Blue Ridge Medical. Additionally, the venture recently received $15 million in growth capital from Trinity Capital to further advance its minimally invasive endovascular interventions.
Cagent Vascular has raised $65.9M across 4 funding rounds.
Cagent Vascular has raised $65.9M in total across 4 funding rounds.
# Cagent Vascular: High-Level Overview
Cagent Vascular is a medical device company developing next-generation angioplasty balloons using proprietary serration technology to treat cardiovascular disease.[2] The company focuses on peripheral artery disease (PAD) and broader cardiovascular conditions, offering a minimally invasive alternative to traditional angioplasty approaches.[1][4] Cagent's core product, the Serranator balloon, is designed to achieve optimal lumen gain—the restoration of blood vessel diameter—while minimizing complications like dissection and recoil that often necessitate stent placement.[6]
The company addresses a significant clinical problem: traditional angioplasty balloons often fail to uniformly expand lesions across all morphologies, leading to suboptimal outcomes and the need for additional interventions. Cagent's serration technology applies concentrated point force along a serrated edge, enabling more predictable arterial expansion and consistent lesion yield with lower dissection rates.[6] Recent momentum includes the October 2025 expansion of the Serranator product line with new 7.0 mm and 8.0 mm sizes, and ongoing clinical validation through studies like the Serranator vs. POBA OCT trial at Columbia University Medical Center initiated in April 2025.[2]
Cagent Vascular operates within the expanding medical device sector focused on cardiovascular disease treatment, a leading cause of mortality worldwide.[2] The company rides the broader trend toward minimally invasive interventions that reduce patient recovery time and healthcare costs compared to surgical alternatives. The timing is favorable: aging populations in developed markets drive demand for cardiovascular treatments, while regulatory pathways for novel medical devices have become more established.
Cagent's serration technology represents an incremental but meaningful innovation—applying well-established physics principles (serration is common in automotive, construction, and aviation) to solve a specific clinical problem.[6] This positions the company within the competitive angioplasty balloon market, where differentiation through superior clinical outcomes can drive adoption among interventional cardiologists and vascular surgeons.
Cagent Vascular is executing a focused strategy: validate serration technology through rigorous clinical trials, expand the product portfolio (evidenced by the 2025 size expansion), and build market adoption among interventional specialists. The company's success depends on clinical evidence demonstrating that the Serranator meaningfully improves patient outcomes and reduces procedural costs compared to traditional balloons and stent-based approaches.
Looking ahead, Cagent's influence will likely grow if clinical data continues to support superior lumen gain and lower complication rates. Broader adoption could reshape treatment protocols for PAD and other cardiovascular conditions, potentially reducing stent utilization and improving patient quality of life. The company's trajectory will be shaped by regulatory clearances, clinical trial results, and its ability to penetrate the interventional cardiology market—a competitive space where clinical evidence and physician relationships are paramount.
Cagent Vascular has raised $65.9M in total across 4 funding rounds.
Cagent Vascular's investors include Trinity Capital, U.S. Venture Partners, Acorn Bioventures, Aisling Capital, Hercules Capital, Sectoral Asset Management.
Cagent Vascular has raised $65.9M across 4 funding rounds. Most recently, it raised $15.0M Other Equity in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 20, 2025 | $15.0M Other Equity | Trinity Capital | |
| Feb 1, 2024 | $30.0M Series C | U.S. Venture Partners | Acorn Bioventures, Aisling Capital, Hercules Capital |
| Jun 17, 2021 | $9.0M Other Equity | Sectoral Asset Management | |
| Jul 12, 2018 | $11.9M Series B |